VIRI News and Press, Virios Therapeutics Inc. From 07/26/21

IMV (IMV) +51%.Tyme Technologies (TYME) +35% granted U.S. patent claims covering use of Tyrosine-based drug delivery method to treat cancerDynatronics (DYNT) +33%.NanoVibronix (NAOV) +33%.Xenetic Biosciences (XBIO) +35% on $12.5M private placementBitfarms  (BITF) +19%.Bit ...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that all 41 sites involved in its ongoing 460 patient Phase 2b fibromyalgia (FM) t...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The big event next week could be the two-day FOMC meeting that will conclude with a policy statement and Jerome Powell p...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...

Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor Corporation (MX) +24%...

Aethlon Medical (AEMD) +280% after publication of its case studies of critically ill COVID-19 patients treated with the Aethlon Hemopurifier®.Checkpoint Therapeutics (CKPT) +50%.Antelope Enterprise Holdings Limited (AEHL) +45%.SPI Energy (SPI) +41% as its group Company is build...

Virios Therapeutics (VIRI) jumps 17% premarket in reaction to the data from its Phase 2a clinical trial PRID-201 evaluating IMC-1 in patients with fibromyalgia ((FM)). IMC‑1 exhibited an encouraging safety profile, as AEs occurred at a lower rate and were less sever...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that data from the company’s Phase 2a clini...

Virios Therapeutics (VIRI) announces the dosing of the first patient in its Phase 2b clinical trial evaluating IMC-1 in patients with pain disorder fibromyalgia.Shares up more than 9% premarket.IMC-1 is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir a...